Lineage Cell Therapeutics (LCTX)

• Market cap: $114M
• 1 day: 5.94%
• 5 days: 6.44%
• 1 month: 10.50%
• 3 months: -20.35%
• 6 months: -41.45%
• Year to date: -3.11%
• 1 year: -54.22%
• 5 years: -41.29%
• 10 years: -45.04%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Employees: 77

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

153% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 15

108% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 13

9% more funds holding

Funds holding: 114 [Q3] → 124 (+10) [Q4]

1.5% less ownership

Funds ownership: 50.08% [Q3] → 48.58% (-1.5%) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

37% less capital invested

Capital invested by funds: $85.6M [Q3] → $53.8M (-$31.8M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2 301% upside
• Avg. target: $4.67 835% upside
• High target: $9 1,704% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

B. Riley Securities Mayank Mamtani 9% 1-year accuracy 2 / 22 met price target	501% upside $3	Buy Maintained	14 Mar 2025
D. Boral Capital Jason Kolbert 28% 1-year accuracy 107 / 376 met price target	301% upside $2	Buy Maintained	11 Mar 2025
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 89 / 416 met price target	1,704% upside $9	Buy Reiterated	11 Mar 2025